Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

References for PMC Articles for PubMed (Select 21517791)

2.

Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials.

Wolfson J, Gilbert P.

Biometrics. 2010 Dec;66(4):1153-61. doi: 10.1111/j.1541-0420.2009.01380.x.

3.

A bayesian approach to surrogacy assessment using principal stratification in clinical trials.

Li Y, Taylor JM, Elliott MR.

Biometrics. 2010 Jun;66(2):523-31. doi: 10.1111/j.1541-0420.2009.01303.x. Epub 2009 Aug 10.

4.

A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies.

Huang Y, Pepe MS.

Biometrics. 2009 Dec;65(4):1133-44. doi: 10.1111/j.1541-0420.2009.01201.x. Epub .

5.

Mediation analysis with principal stratification.

Gallop R, Small DS, Lin JY, Elliott MR, Joffe M, Ten Have TR.

Stat Med. 2009 Mar 30;28(7):1108-30. doi: 10.1002/sim.3533.

6.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.

7.

Related causal frameworks for surrogate outcomes.

Joffe MM, Greene T.

Biometrics. 2009 Jun;65(2):530-8. doi: 10.1111/j.1541-0420.2008.01106.x.

PMID:
18759836
8.

Evaluating candidate principal surrogate endpoints.

Gilbert PB, Hudgens MG.

Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.

9.

Integrating the predictiveness of a marker with its performance as a classifier.

Pepe MS, Feng Z, Huang Y, Longton G, Prentice R, Thompson IM, Zheng Y.

Am J Epidemiol. 2008 Feb 1;167(3):362-8. Epub 2007 Nov 2.

10.

Evaluating the predictiveness of a continuous marker.

Huang Y, Sullivan Pepe M, Feng Z.

Biometrics. 2007 Dec;63(4):1181-8. Epub 2007 May 8.

11.
12.

Counterfactual links to the proportion of treatment effect explained by a surrogate marker.

Taylor JM, Wang Y, ThiƩbaut R.

Biometrics. 2005 Dec;61(4):1102-11.

PMID:
16401284
13.

Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Weir CJ, Walley RJ.

Stat Med. 2006 Jan 30;25(2):183-203. Review.

PMID:
16252272
14.

Index for rating diagnostic tests.

YOUDEN WJ.

Cancer. 1950 Jan;3(1):32-5. No abstract available.

PMID:
15405679
15.

The validation of surrogate endpoints in meta-analyses of randomized experiments.

Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H.

Biostatistics. 2000 Mar;1(1):49-67.

16.

Statistical challenges in the evaluation of surrogate endpoints in randomized trials.

Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T, Alonso A.

Control Clin Trials. 2002 Dec;23(6):607-25. Review.

PMID:
12505240
17.

Principal stratification in causal inference.

Frangakis CE, Rubin DB.

Biometrics. 2002 Mar;58(1):21-9.

18.

Meta-analysis for the evaluation of potential surrogate markers.

Daniels MJ, Hughes MD.

Stat Med. 1997 Sep 15;16(17):1965-82.

PMID:
9304767
19.

Estimating the proportion of treatment effect explained by a surrogate marker.

Lin DY, Fleming TR, De Gruttola V.

Stat Med. 1997 Jul 15;16(13):1515-27.

PMID:
9249922
20.

Surrogate end points in clinical trials: are we being misled?

Fleming TR, DeMets DL.

Ann Intern Med. 1996 Oct 1;125(7):605-13. Review. No abstract available.

PMID:
8815760
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk